A Phase 2, Randomized, Open-Label, Parallel Group Study Evaluating the Safety and Efficacy of TAK-385, an Oral Gonadotropin-Releasing Hormone (GnRH) Antagonist, for Patients With Localized Prostate Cancer Requiring Neoadjuvant and Adjuvant Androgen Deprivation Therapy With External Beam Radiation Therapy (EBRT)

Trial Profile

A Phase 2, Randomized, Open-Label, Parallel Group Study Evaluating the Safety and Efficacy of TAK-385, an Oral Gonadotropin-Releasing Hormone (GnRH) Antagonist, for Patients With Localized Prostate Cancer Requiring Neoadjuvant and Adjuvant Androgen Deprivation Therapy With External Beam Radiation Therapy (EBRT)

Completed
Phase of Trial: Phase II

Latest Information Update: 19 Apr 2017

At a glance

  • Drugs Relugolix (Primary) ; Degarelix
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Sponsors Takeda Oncology
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 11 Oct 2016 Results assessing testosterone lowering efficacy, safety and pharmacokinetics of Relugolix verses Degarelix presented at the 41st European Society for Medical Oncology Congress.
    • 06 May 2016 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top